<PAGE> 1
-----------------------------
OMB APPROVAL
-----------------------------
OMB Number: 3235-0145
Expires: October 31, 2002
Estimated average burden
hours per response 14.90
-----------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D/A
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 2)*
Miravant Medical Technologies
- --------------------------------------------------------------------------------
(NAME OF ISSUER)
Common Stock, Par Value $0.01 Per Share
- --------------------------------------------------------------------------------
(TITLE OF CLASS OF SECURITIES)
69329P103
---------------------------------------------
(CUSIP NUMBER)
Richard T. Collier
Senior Vice President
and General Counsel
Pharmacia Corporation
100 Route 206 North
Peapack, New Jersey 07977
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive
Notices and Communications)
March 31, 2000
---------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check
the following box [ ].
NOTE: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Section 240.13d-7 for
other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
SEC 1746(12-91)
<PAGE> 2
SCHEDULE 13D/A
<TABLE>
<S> <C>
- ------------------------------ ---------------------------------
CUSIP NO. 69329P103 PAGE 2 OF 24 PAGES
------------------- ------ --------
- ------------------------------ --------------------------------
- --------------------------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
Pharmacia & Upjohn Treasury Services AB
- --------------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [ ]
(b) [ ]
- --------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------------------------
4 SOURCE OF FUNDS (SEE INSTRUCTIONS)
WC
- --------------------------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
- --------------------------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Sweden
- --------------------------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF
SHARES
BENEFICIALLY 240,000
OWNED BY ---------------------------------------------------------------------------------
EACH 8 SHARED VOTING POWER
REPORTING
PERSON -0-
WITH ----------------------------------------------------------------------------------
9 SOLE DISPOSITIVE POWER
240,000
---------------------------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
-0-
- --------------------------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
240,000
- --------------------------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
- --------------------------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
1.3%
- --------------------------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
- --------------------------------------------------------------------------------------------------
</TABLE>
<PAGE> 3
SCHEDULE 13D/A
<TABLE>
<S> <C>
- --------------------------- ------------------------------------
CUSIP NO. 69329P103 PAGE 3 OF 24 PAGES
---------------- ------- ---------
- --------------------------- ------------------------------------
- -------------------------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
Pharmacia & Upjohn Company
- -------------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [ ]
(b) [ ]
- -------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------------------------
4 SOURCE OF FUNDS (SEE INSTRUCTIONS)
WC
- -------------------------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
- -------------------------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- -------------------------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY 125,001
OWNED BY
EACH ------------------------------------------------------------------------------
REPORTING 8 SHARED VOTING POWER
PERSON
WITH
-0-
------------------------------------------------------------------------------
9 SOLE DISPOSITIVE POWER
125,001
------------------------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
-0-
- -------------------------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
125,001
- -------------------------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
- -------------------------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.7%
- -------------------------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
- -------------------------------------------------------------------------------------------------
</TABLE>
<PAGE> 4
SCHEDULE 13D/A
<TABLE>
<S> <C>
- ------------------------------ ----------------------------------------
CUSIP NO. 69329P103 PAGE 4 OF 24 PAGES
------------------- --------- -----------
- ------------------------------ ----------------------------------------
- -----------------------------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
Pharmacia & Upjohn S.p.A.
- -----------------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [ ]
(b) [ ]
- -----------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- -----------------------------------------------------------------------------------------------------
4 SOURCE OF FUNDS (SEE INSTRUCTIONS)
WC
- -----------------------------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
- -----------------------------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Italy
- -----------------------------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY 1,736,533
OWNED BY ---------------------------------------------------------------------------------
EACH 8 SHARED VOTING POWER
REPORTING
PERSON -0-
WITH ---------------------------------------------------------------------------------
9 SOLE DISPOSITIVE POWER
1,736,533
--------------------------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
-0-
- -----------------------------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,736,533
- -----------------------------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
- -----------------------------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
9.4%
- -----------------------------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
- -----------------------------------------------------------------------------------------------------
</TABLE>
<PAGE> 5
SCHEDULE 13D/A
<TABLE>
<S> <C>
- ------------------------------ ----------------------------------------
CUSIP NO. 69329P103 PAGE 5 OF 24 PAGES
------------------- --------- -----------
- ------------------------------ ----------------------------------------
- -----------------------------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
Pharmacia & Upjohn AB
- -----------------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [ ]
(b) [ ]
- -----------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- -----------------------------------------------------------------------------------------------------
4 SOURCE OF FUNDS (SEE INSTRUCTIONS)
AF
- -----------------------------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
- -----------------------------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Sweden
- -----------------------------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY 1,976,533
OWNED BY ----------------------------------------------------------------------------------
EACH 8 SHARED VOTING POWER
REPORTING
PERSON -0-
WITH ----------------------------------------------------------------------------------
9 SOLE DISPOSITIVE POWER
1,976,533
----------------------------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
-0-
- -----------------------------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,976,533
- -----------------------------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
- -----------------------------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
10.7%
- -----------------------------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
- -----------------------------------------------------------------------------------------------------
</TABLE>
<PAGE> 6
SCHEDULE 13D/A
<TABLE>
<S> <C>
- ------------------------------ ----------------------------------------
CUSIP NO. 69329P103 PAGE 6 OF 24 PAGES
------------------- --------- -----------
- ------------------------------ ----------------------------------------
- ---------------------------------------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
Pharmacia & Upjohn Holdings B.V.
- ---------------------------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [ ]
(b) [ ]
- ---------------------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- ---------------------------------------------------------------------------------------------------------------
4 SOURCE OF FUNDS (SEE INSTRUCTIONS)
AF
- ---------------------------------------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
- ---------------------------------------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Netherlands
- ---------------------------------------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY 1,976,533
OWNED BY ----------------------------------------------------------------------------------------------
EACH 8 SHARED VOTING POWER
REPORTING
PERSON -0-
WITH ----------------------------------------------------------------------------------------------
9 SOLE DISPOSITIVE POWER
1,976,533
----------------------------------------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
-0-
- ---------------------------------------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,976,533
- ---------------------------------------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
- ---------------------------------------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
10.7%
- ---------------------------------------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
OO *
- ---------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE> 7
SCHEDULE 13D
<TABLE>
<S> <C>
- ------------------------------ ----------------------------------------
CUSIP NO. 69329P103 PAGE 7 OF 24 PAGES
------------------- --------- -----------
- ------------------------------ ----------------------------------------
- ---------------------------------------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
Pharmacia & Upjohn, Inc.
- ---------------------------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [ ]
(b) [ ]
- ---------------------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- ---------------------------------------------------------------------------------------------------------------
4 SOURCE OF FUNDS (SEE INSTRUCTIONS)
AF
- ---------------------------------------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
- ---------------------------------------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- ---------------------------------------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY 2,101,534
OWNED BY -------------------------------------------------------------------------------------------
EACH 8 SHARED VOTING POWER
REPORTING
PERSON -0-
WITH -------------------------------------------------------------------------------------------
9 SOLE DISPOSITIVE POWER
2,101,534
-------------------------------------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
-0-
- --------------------------------------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,101,534
- ---------------------------------------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
- ---------------------------------------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
11.4%
- ---------------------------------------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
- ---------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE> 8
SCHEDULE 13D/A
<TABLE>
<S> <C>
- ------------------------------ ----------------------------------------
CUSIP NO. 69329P103 PAGE 8 OF 24 PAGES
------------------- --------- -----------
- ------------------------------ ----------------------------------------
- ----------------------------------------------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
Pharmacia Corporation
- ----------------------------------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [ ]
(b) [ ]
- ----------------------------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- ----------------------------------------------------------------------------------------------------------------------
4 SOURCE OF FUNDS (SEE INSTRUCTIONS)
AF
- ----------------------------------------------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
- ----------------------------------------------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- ----------------------------------------------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY 2,101,534
OWNED BY
EACH
REPORTING
PERSON --------------------------------------------------------------------------------------------------
WITH 8 SHARED VOTING POWER
-0-
--------------------------------------------------------------------------------------------------
9 SOLE DISPOSITIVE POWER
2,101,534
--------------------------------------------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
-0-
- ---------------------------------------------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,101,534
- ---------------------------------------------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
- ---------------------------------------------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
11.4%
- ---------------------------------------------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO, HC
- ---------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE> 9
CUSIP Number: 69329P103 Page 9 of 24
Pharmacia & Upjohn AB (formerly Pharmacia AB), a Swedish corporation
("P&U AB"), Pharmacia & Upjohn S.p.A. (formerly Pharmacia S.p.A.), an Italian
corporation ("P&U S.p.A."), Pharmacia & Upjohn Company, a Delaware corporation
("P&U Co."), Pharmacia & Upjohn Holdings BV, a "check the box" entity
incorporated in the Netherlands ("P&U BV") and Pharmacia & Upjohn, Inc. ("P&U
Inc.", and together with P&U AB, P&U S.p.A., P&U Co. and P&U BV, the "Original
Reporting Persons"), Pharmacia & Upjohn Treasury Services AB, a Swedish
corporation ("P&U Treasury") and Pharmacia Corporation (formerly Monsanto
Company), a Delaware corporation ("PHA", and together with P&U Treasury and the
Original Reporting Persons the "Reporting Persons") hereby amend the report on
Schedule 13D (the "Original Schedule 13D") filed by the Original Reporting
Persons on March 1, 1999, as amended by the report on Schedule 13D/A filed by
the Original Reporting Persons and P&U Treasury on December 15, 1999, with
respect to shares of Common Stock, par value $.01 per share (the "Shares"), of
Miravant Medical Technologies (formerly PDT, Inc.), a Delaware corporation
("Miravant"), beneficially owned by them. Capitalized terms used but not
defined herein shall have the meaning attributed to such terms in the Original
Schedule 13D.
ITEM 2. IDENTITY AND BACKGROUND
Item 2 of the Original Schedule 13D is amended in its entirety as
follows:
This statement is being filed by P&U Treasury, P&U AB, P&U S.p.A., P&U
Co., P&U BV, P&U Inc., and PHA.
On December 19, 1999, P&U Inc., PHA, and MP Sub, Incorporated, a
Delaware corporation and a direct wholly owned subsidiary of PHA entered into
an Agreement and Plan of Merger, as amended (the "Merger Agreement"). On March
31, 2000, pursuant to the Merger Agreement, MP Sub merged (the "Merger") with
and into P&U Inc., as a result of which P&U Inc. became a direct wholly owned
subsidiary of PHA and P&U AB, P&U S.p.A, P&U Co., P&U BV and P&U Treasury
became indirect wholly owned subsidiaries of PHA.
<PAGE> 10
CUSIP Number: 69329P103 Page 10 of 24
The principal business address of P&U S.p.A. is Pharmacia & Upjohn
S.p.A., via Robert Koch 1.2, 75017 Milan, Italy. The principal business address
of P&U AB and P&U Treasury is Pharmacia & Upjohn AB, S-171 97 Stockholm,
Sweden. The principal business address of P&U BV is Pharmacia & Upjohn Holdings
B.V., Houttuinlaan 4, NL - 3447 GM Woerden, The Netherlands. The principal
business address of P&U Inc., P&U Co. and PHA is 100 Route 206 North, Peapack,
New Jersey 07977.
P&U Treasury, a Swedish corporation, and P&U S.p.A., an Italian
corporation, are each subsidiaries of P&U AB, a Swedish corporation, which, in
turn, is a wholly owned subsidiary of P&U BV, a "check the box" entity
incorporated in the Netherlands. P&U BV and P&U Co. are wholly owned
subsidiaries of P&U Inc., a Delaware corporation. P&U Co., a Delaware
corporation, is the successor in interest to Pharmacia, Inc., a Minnesota
corporation and a former wholly owned subsidiary of P&U AB. P&U Inc. is a wholly
owned subsidiary of PHA. The principal business of each of the Reporting Persons
is the development, production, marketing and sale of pharmaceutical products.
In addition, PHA has one of the world's leading fully integrated agricultural
businesses.
The name, residence or business address, present principal occupation or
employment, and the citizenship of each director and executive officer of (i)
P&U S.p.A. is set forth in Schedule I hereto and incorporated herein by
reference, (ii) P&U Co. is set forth in Schedule II hereto and incorporated
herein by reference, (iii) P&U Treasury is set forth in Schedule III hereto
and incorporated herein by reference and (iv) PHA is set forth in Schedule IV
hereto and incorporated herein by reference.
None of the Reporting Persons, or to the best knowledge and belief of
the Reporting Persons, any of the individuals listed in Schedule I, II, III or
IV has, during the past five years, been convicted in any criminal proceeding
(excluding traffic violations or similar misdemeanors) or has been a party to a
civil proceeding of a judicial or administrative body of competent jurisdiction
and as a result of such proceeding was or is subject to a judgment, decree or
final order enjoining future violations of, or prohibiting or mandating
activities subject to, federal or state securities laws or finding any violation
with respect to such laws.
This Item 2 is qualified in its entirety by reference to Schedules I,
II, III and IV which are incorporated herein by reference.
<PAGE> 11
CUSIP Number: 69329P103 Page 11 of 24
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
Item 5 of the Original Schedule 13D is amended in its entirety as
follows:
(a) The percentage interest held by each Reporting Person presented
below is based on the number of Shares reported to be outstanding as of March
10, 2000 in Miravant's Annual Report on Form 10-K, for the fiscal year ended
December 31, 1999, filed March 30, 2000, as adjusted to give effect to the
issuance of the Shares issued pursuant to the warrants issued to P&U Treasury in
connection with the loans made to Miravant on June 9, 1999 and December 13, 1999
(the "Outstanding Shares").
P&U Co., as successor to Pharmacia, Inc., beneficially owns 125,001
Shares, representing approximately 0.7% of the Outstanding Shares.
P&U S.p.A. beneficially owns 1,736,533 Shares, representing
approximately 9.4% of the Outstanding Shares.
P&U Treasury beneficially owns 240,000 Shares, representing
approximately 1.3% of the Outstanding Shares.
P&U AB may be deemed to beneficially own 1,976,533 Shares, representing
approximately 10.7% of the Outstanding Shares.
P&U BV may be deemed to beneficially own 1,976,533 Shares, representing
approximately 10.7% of the Outstanding Shares.
P&U Inc. may be deemed to beneficially own 2,101,534 Shares,
representing approximately 11.4% of the Outstanding Shares.
PHA may be deemed to beneficially own 2,101,534 Shares, representing
approximately 11.4% of the Outstanding Shares.
None of the Reporting Persons, and to the knowledge of the Reporting
Persons, none of the persons listed in Schedules I, II, III and IV
beneficially owns any Shares other than as set forth herein.
<PAGE> 12
CUSIP Number: 69329P103 Page 12 of 24
(b) Each Reporting Person has the power to vote or direct the vote and
dispose or direct the disposition of the Shares beneficially owned by such
Reporting Persons as indicated in pages 2 through 8 above.
(c) Except as described herein, none of the Reporting Persons and, to
the knowledge of the Reporting Persons, none of the persons listed on Schedule
I, II, III or IV has been party to any transaction in Shares during the past
sixty days.
(d) No other person has the right to receive or the power to direct the
receipt of dividends from or proceeds from the sale of Shares.
(e) Not Applicable.
The foregoing discussion is qualified in its entirety by reference to
the Stock Purchase Agreement, the 1994 Stock Purchase Agreement, the PDT
Warrant, the Equity Investment Agreement, the Registration Rights Agreement, the
Warrant Agreement and the Credit Agreement each of which is incorporated herein
by reference.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS
Exhibit number I of the Original Schedule 13D is amended as follows:
Exhibit No. Exhibit Description
----------- -------------------
I Joint Filing Agreement, dated as of April 10, 2000
<PAGE> 13
CUSIP Number: 69329P103 Page 13 of 24
SIGNATURE
After reasonable inquiry and to the best of our knowledge and belief, we
certify that the information set forth in this statement is true, complete and
correct.
Dated: April 10, 2000
PHARMACIA & UPJOHN TREASURY
SERVICES AB
By: /s/ Sofi Eriksson
------------------------------
Name: Sofi Eriksson
Title: Director
PHARMACIA & UPJOHN COMPANY
By: /s/ Don W. Schmitz
------------------------------
Name: Don W. Schmitz
Title: Secretary
PHARMACIA & UPJOHN S.p.A.
By: /s/ Francesco Granata
------------------------------
Name: Francesco Granata
Title: Managing Director
PHARMACIA & UPJOHN AB
By: /s/ Hakan Astrom
------------------------------
Name: Hakan Astrom
Title: Managing Director
<PAGE> 14
CUSIP Number: 69329P103 Page 14 of 24
PHARMACIA & UPJOHN HOLDINGS B.V.
By: /s/ Wim Kuiper
------------------------------
Name: Wim Kuiper
Title: Director
PHARMACIA & UPJOHN, INC.
By: /s/ Don W. Schmitz
------------------------------
Name: Don W. Schmitz
Title: Secretary
PHARMACIA CORPORATION
By: /s/ Don W. Schmitz
------------------------------
Name: Don W. Schmitz
Title: Secretary
<PAGE> 15
CUSIP Number: 69329P103 Page 15 of 24
SCHEDULE I
Name, Business Address, Principal Occupation or Employment and
Citizenship of all Directors and Executive Officers of Pharmacia & Upjohn
S.p.A.:
Board of Directors:
- ------------------
Maurizio Premoli
Director
Pharmacia & Upjohn S.p.A.
via Robert Koch 1.2
20152 Milan, Italy
Citizenship: Italy
Emanuele Barie
Director & Secretary
Pharmacia & Upjohn S.p.A.
via Robert Koch 1.2
20152 Milan, Italy
Citizenship: Italy
Francesco Granata
Managing Director
Pharmacia & Upjohn S.p.A.
via Robert Koch 1.2
20152 Milan, Italy
Citizenship: Italy
Executive Officers:
- ------------------
Francesco Granata
Managing Director
Pharmacia & Upjohn S.p.A.
via Robert Koch 1.2
20152 Milan, Italy
Citizenship: Italy
<PAGE> 16
CUSIP Number: 69329P103 Page 16 of 24
SCHEDULE II
Name, Business Address, Principal Occupation or Employment and
Citizenship of all Directors and Executive Officers of Pharmacia & Upjohn
Company:
Board of Directors:
- ------------------
Fred Hassan
President and Chief Executive Officer
Pharmacia Corporation
100 Route 206 North
Peapack, NJ 07977
Citizenship: United States
Christopher J. Coughlin
Executive Vice President and Chief Financial Officer
Pharmacia Corporation
100 Route 206 North
Peapack, NJ 07977
Citizenship: United States
Richard T. Collier
Senior Vice President and General Counsel
Pharmacia Corporation
100 Route 206 North
Peapack, NJ 07977
Citizenship: United States
Executive Officers:
- ------------------
Fred Hassan
President and Chief Executive Officer
100 Route 206 North
Peapack, NJ 07977
Citizenship: United States
Goran A. Ando, M.D.
Executive Vice President
100 Route 206 North
Peapack, NJ 07977
Citizenship: Sweden
<PAGE> 17
CUSIP Number: 69329P103 Page 17 of 24
Christopher J. Coughlin
Executive Vice President and Chief Financial Officer
100 Route 206 North
Peapack, NJ 07977
Citizenship: United States
Timothy G. Rothwell
Executive Vice President
100 Route 206 North
Peapack, NJ 07977
Citizenship: United States
Hakan Astrom
Senior Vice President
100 Route 206 North
Peapack, NJ 07977
Citizenship: Sweden
Richard T. Collier
Senior Vice President and Assistant Secretary
100 Route 206 North
Peapack, NJ 07977
Citizenship: United States
Carrie Smith Cox
Senior Vice President
100 Route 206 North
Peapack, NJ 07977
Citizenship: United States
Mats Pettersson
Senior Vice President
100 Route 206 North
Peapack, NJ 07977
Citizenship: Sweden
<PAGE> 18
CUSIP Number: 69329P103 Page 18 of 24
SCHEDULE III
Name, Business Address, Principal Occupation or Employment and
Citizenship of all Directors and Executive Officers of Pharmacia & Upjohn
Treasury Services AB:
Board of Directors:
- ------------------
Per Aberg
Pharmacia & Upjohn AB
S-171 97 Stockholm, Sweden
Citizenship: Sweden
Sofi Eriksson
Pharmacia & Upjohn AB
S-171 97 Stockholm, Sweden
Citizenship: Sweden
Executive Officers:
- ------------------
None.
<PAGE> 19
CUSIP Number: 69329P103 Page 19 of 24
SCHEDULE IV
Name, Business Address, Principal Occupation or Employment and
Citizenship of all Directors and Executive Officers of Pharmacia Corporation:
Board of Directors:
- ------------------
Frank C. Carlucci
Chairman, The Carlyle Group
Suite 220S
1001 Pennsylvania Avenue, N.W.
Washington, DC 20004-2505
Citizenship: United States
Richard U. De Schutter
Senior Executive Vice President and
Chief Administrative Officer
Pharmacia Corporation
100 Route 206 North
Peapack, NJ 07977
Citizenship: United States
M. Kathryn Eickhoff
President, Eickhoff Economics
Suite 502
670 Broadway
New York, NY 10012
Citizenship: United States
Fred Hassan
President and Chief Executive Officer, Pharmacia Corporation
100 Route 206 North
Peapack, NJ 07977
Citizenship: United States
Michael Kantor
Partner, Mayer, Brown, & Platt
100 Route 206 North
Peapack, NJ 07977
Citizenship: United States
<PAGE> 20
CUSIP Number: 69329P103 Page 20 of 24
Gwendolyn S. King
Retired Senior Vice President,
Corporate and Public Affairs, PECO
Energy Company
100 Route 206 North
Peapack, NJ 07977
Citizenship: United States
Philip Leder
Chairman, Department of Genetics,
Harvard Medical School, and Senior
Investigator, Howard Hughes
Medical Institute.
200 Longwood Avenue
Boston, MA 02115
Citizenship: United States
R.L. Berthold Lindqvist
Former President & CEO, Gambro AB
Gamlegardsvagen 50
S-216 20 Malmo, Sweden
Citizenship: Sweden
Olof Lund
Chairman, Enator AB
Lojtnantsgatan 21
S-115 93 Stockholm, Sweden
Citizenship: Sweden
C. Steven McMillan
President and COO, Sara Lee Corporation
Suite 4600
Three First National Plaza
70 W. Madison
Chicago, IL 60602
Citizenship: United States
William U. Parfet
Co-Chairman, MPI Research
54943 N. Main Street
Mattawan, MI 49071
Citizenship: United States
<PAGE> 21
CUSIP Number: 69329P103 Page 21 of 24
Jacobus F.M. Peters
Retired Chairman of the Executive Board
and Chief Executive Officer, Aegon N.V.
Dennenlaan 15
2244 AK Wassenaar
The Netherlands
Citizenship: the Netherlands
John S. Reed
Chairman and Co-Chief Executive Officer,
Citigroup Inc.
153 E. 53rd Street, 4th Floor
New York, NY 10043
Citizenship: United States
<PAGE> 22
CUSIP Number: 69329P103 Page 22 of 24
Ulla B. Reinius
President, Finansfakta R. AB
Sibyllegatam 5
S-114 51 Stockholm, Sweden
Citizenship: Sweden
John E. Robson
Senior Advisor, Robertson Stephens Inc.
555 California Street
San Francisco, CA 94104
Citizenship: United States
William D. Ruckelshaus
Principal, Madrona Investment Group L.L.C.
1000 Second Avenue, Suite 3700
Seattle, WA 98104
Citizenship: United States
Bengt I. Samuelsson
Professor, Karolinska Institutet
Department of MBB, Div. Chemistry II
Karolinska Institutet, Solna
S-171 77 Stockholm, Sweden
Citizenship: Sweden
Robert B. Shapiro
Chairman of the Board of Directors,
Pharmacia Corporation
Suite 900
200 World Trade Center-Chicago
Chicago, Il 60654-1001
Citizenship: United States
<PAGE> 23
CUSIP Number: 69329P103 Page 23 of 24
Executive Officers:
- ------------------
Fred Hassan
CEO
100 Route 206 North
Peapack, NJ 07977
Citizenship: United States
Richard U. De Schutter
Senior Executive Vice President and
Chief Administrative Officer
100 Route 206 North
Peapack, NJ 07977
Citizenship: United States
Philip Needleman
Senior Executive Vice President,
Chief Scientific Officer, and
Chairman, Research & Development
100 Route 206 North
Peapack, NJ 07977
Citizenship: United States
Goran A. Ando, M.D.
Executive Vice President and
President, Research and Development
100 Route 206 North
Peapack, NJ 07977
Citizenship: Sweden
Christopher J. Coughlin
Executive Vice President and Chief Financial Officer
100 Route 206 North
Peapack, NJ 07977
Citizenship: United States
Timothy G. Rothwell
Executive Vice President and President,
Global Pharmaceutical Operations
100 Route 206 North
Peapack, NJ 07977
Citizenship: United States
Hakan Astrom
Senior Vice President,
Investor Relations and Strategy
100 Route 206 North
Peapack, NJ 07977
Citizenship: Sweden
<PAGE> 24
CUSIP Number: 69329P103 Page 24 of 24
Richard T. Collier
Senior Vice President and General Counsel
100 Route 206 North
Peapack, NJ 07977
Citizenship: United States
Carrie Smith Cox
Executive Vice President and
Head, Global Business Management
100 Route 206 North
Peapack, NJ 07977
Citizenship: United States
Mats Pettersson
Senior Vice President
100 Route 206 North
Peapack, NJ 07977
Citizenship: Sweden
Alan L. Heller
Executive Vice President and
Head, G. D. Searle & Co. Operations
100 Route 206 North
Peapack, NJ 07977
Citizenship: United States
Stephen P. McMillan
Sector Vice President, Global
Specialty Operations
100 Route 206 North
Peapack, NJ 07977
Citizenship: United States
Birgitta Klasen
Senior Vice President, Information
Technology
100 Route 206 North
Peapack, NJ 07977
Citizenship: Sweden
Paul Matson
Senior Vice President, Human
Resources
100 Route 206 North
Peapack, NJ 07977
Citizenship: United States
Joan H. Walker
Senior Vice President, Public
Affairs
100 Route 206 North
Peapack, NJ 07977
Citizenship: United States
<PAGE> 25
INDEX TO EXHIBITS
Exhibit Numbers Exhibit
- --------------- -------
99.1 Joint Filing Agreement, dated as of April 10, 2000
<PAGE> 1
EX-99.1
EXHIBIT I
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k)(1) promulgated under the Securities
Exchange Act of 1934, the undersigned agree to the joint filing of a Statement
on Schedule 13D (including any and all amendments thereto) with respect to the
Common Stock, $0.01 par value, of Miravant Medical Technologies, and further
agree to the filing of this agreement as an Exhibit thereto. In addition, each
party to this Agreement expressly authorizes each other party to this Agreement
to file on its behalf any and all amendments to such Statement on Schedule 13D.
Dated: April 10, 2000
PHARMACIA & UPJOHN TREASURY SERVICES AB
By: /s/ Sofi Eriksson
------------------------------
Name: Sofi Eriksson
Title: Director
PHARMACIA & UPJOHN COMPANY
By: /s/ Don W. Schmitz
------------------------------
Name: Don W. Schmitz
Title: Secretary
PHARMACIA & UPJOHN S.p.A.
By: /s/ Francesco Granata
------------------------------
Name: Francesco Granata
Title: Managing Director
<PAGE> 2
PHARMACIA & UPJOHN AB
By: /s/ Hakan Astrom
-------------------------------
Name: Hakan Astrom
Title: Managing Director
PHARMACIA & UPJOHN HOLDINGS B.V.
By: /s/ Wim Kuiper
-------------------------------
Name: Wim Kuiper
Title: Director
PHARMACIA & UPJOHN, INC.
By: /s/ Don W. Schmitz
-------------------------------
Name: Don W. Schmitz
Title: Secretary
PHARMACIA CORPORATION
By: /s/ Don W. Schmitz
-------------------------------
Name: Don W. Schmitz
Title: Secretary
